Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

The ‘next Ozempic’ became a social media sensation. Then everything changed

When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily…

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

The 5 Safest Stocks You Can Buy in 2023

The stock market might remain volatile in the near term amid the still-alarmingly high inflation and the anticipated continuation of rate hikes. Therefore, fundamentally strong Eli Lilly (LLY), Novartis (NVS), Comcast (CMCSA), HCA Healthcare (HCA), and Myers Industries (MYE), which pay steady dividends, might be safe buys now. Read more.

StockNews.com

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

Eli Lilly Dives After A 'Bump In The Road' Shakes Its Newest Diabetes Drug

Eli Lilly experienced a "bump in the road" for its newest diabetes treatment, Mounjaro, an analyst said Thursday as LLY stock toppled.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Eli Lilly Tops Q4 Earnings Forecast, Lifts 2023 Outlook, On Trulicity Strength

"Over the course of this critical year, we hope to launch as many as four new medicines for challenging diseases, while advancing our next generation of molecules currently in Phase 3." said CEO David Ricks.

The Street

In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug

Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimer's treatment.

Investors Business Daily

Lilly shares slip as FDA seeks more Alzheimer's drug data

Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment

The Independent UK

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Tribune News Service

How Novo Nordisk Just Expanded Its Diabetes Lead Over Pfizer, Eli Lilly

The Food and Drug Administration expanded the label for Novo Nordisk's oral diabetes medicine, leading NVO stock to jump Friday.

Investors Business Daily

IBD Stock Of The Day: How These Issues In 2023 Could Spark, Or Slam, Eli Lilly Stock

Eli Lilly is the IBD Stock Of The Day as the company explores new methods of treating Alzheimer's and obesity, driving LLY stock near highs.

Investors Business Daily

A TikTok trend sold out Ozempic, leaving people with diabetes dizzy, scared

For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn’t been able to get his diabetes medication.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock

Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs.

StockNews.com

3 Large-Cap Stocks to Add to Your Portfolio Now

The Fed’s aggressive stance on inflation has weighed heavily on the stock market this year. As large-cap stocks usually can weather challenging economic conditions, sound large-cap stocks Eli Lilly (LLY), Agilent Technologies (A), and Fortinet (FTNT) might be wise additions to your portfolio. Keep reading.

Investors Business Daily

The Bullish Call Eli Lilly Made For Its Next-Gen Obesity Drug, A Rival To Novo, Amgen

Eli Lilly said Tuesday it plans to advance its next-generation obesity treatment into final-phase testing, but LLY stock dipped on guidance.

Investors Business Daily

How An Eli Lilly Decision Could Light Up The Red-Hot Obesity Landscape — Again

A key decision from Eli Lilly could alight the obesity treatment landscape again, an analyst said Friday as LLY stock lingers near a record.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Here's What We Know So Far About Amgen's Obesity Drug As It Trails Novo Nordisk, Eli Lilly

Amgen is years behind rivals in developing an obesity treatment, but the company says its experimental drug could prove superior.

Investors Business Daily

Amgen Is The Underdog In Obesity Treatment — But It's Creeping Up On Novo Nordisk, Eli Lilly

Amgen stock dipped Thursday though the company unveiled promising results for its experimental obesity treatment.

Investors Business Daily

Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads

Eli Lilly reportedly is pulling advertising from Twitter after a fake account promised free insulin in a fiasco that depressed LLY stock.

ABC News

Pharmaceutical giant Eli Lilly & Co apologises after fake Twitter account says insulin is free as Elon Musk rolls back verification

The incident is among a wave of impersonations that prompted Twitter to make its relaunched premium service unavailable.

Fortune

No, insulin is not free: Eli Lilly is the latest high-profile casualty of Elon Musk’s Twitter verification mess

Eli Lilly shares fell after pranksters using Twitter Blue impersonated it and made a surprising claim—and this might be just the beginning.

The Independent UK

Pharmaceutical companies’ stocks dive after verified imposter Twitter account claims ‘insulin is free’

Insulin producers Eli Lilly, Novo Nordisk and Sanofi all reported losses during Friday’s trading

Investors Business Daily

Eli Lilly Dives After Fake Twitter Account Promises Free Insulin; Takes Novo Nordisk, Sanofi With It

Twitter's new verification system shook Eli Lilly — leading LLY stock to skid Friday — after a fake account claimed "insulin is free now."

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.